Biofortuna is a specialisest in stabilising molecular reagents by using proprietary freeze dried technology.
The company has made a significant investment in its production capabilities to include plate coating, washing, drying and quality control.
This focus on immunoassay products will complement Biofortuna’s molecular In vitro diagnostics services.
These include ISO 13485 accredited and FDA registered contract research, lyophilisation, air-drying, manufacturing, dispensing and kitting of diagnostic products.
Dr Simon Douglas, Biofortuna CEO, commented: “The success and growth of current projects has fuelled the desire to increase our immunoassay offering.
He added that the expansion will allow for large scale manufacturing of kits based on enzyme-linked immunosorbent assays (ELISA), designed for detecting peptides, proteins, antibodies and hormones.